Whether you’re sorting out the symptoms of an undiagnosed condition or grappling with the weight of a recent diagnosis, gastroparesis can be a complicated and daunting disease to navigate. You’ll ...
Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to oral metoclopramide SOLANA BEACH, Calif., Dec. 19, 2024 ...
Tonix Pharmaceuticals launched a campaign to highlight gastroparesis' impact on oral migraine medication absorption, promoting non-oral treatments. Gastroparesis, often comorbid with migraines, ...
SOLANA BEACH, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (EVOK) (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases ...
Evoke Pharma, Inc. announces its commitment to addressing the needs of patients with gastroparesis following the FDA's update indicating that the supply of unapproved domperidone, used internationally ...
Evoke Pharma, Inc. announced that it has received a Notice of Allowance from the USPTO for a patent application covering the use of its GIMOTI® (metoclopramide) nasal spray in patients with moderate ...
A recent study published by the Journal of the American Medical Association (JAMA) found that patients taking the drugs Ozempic (semaglutide) and Wegovy (liraglutide) for weight loss were more than ...
NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Report with the AI impact on market trends - The global gastroparesis drugs market size is estimated to grow by USD 1.34 billion from 2025-2029, according to ...
NEW YORK, Dec. 15, 2024 /PRNewswire/ -- The global gastroparesis drugs market size is estimated to grow by USD 1.42 billion from 2024 to 2028, according to Technavio. The market is estimated to grow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results